RELA Drug Patent Profile
✉ Email this page to a colleague
When do Rela patents expire, and what generic alternatives are available?
Rela is a drug marketed by Schering and Smithkline Beecham and is included in two NDAs.
The generic ingredient in RELA is nabumetone. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the nabumetone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rela
A generic version of RELA was approved as nabumetone by CHARTWELL RX on February 25th, 2002.
Summary for RELA
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 83 |
Patent Applications: | 3,876 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RELA at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for RELA
US Patents and Regulatory Information for RELA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | RELA | carisoprodol | TABLET;ORAL | 012155-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-001 | Dec 24, 1991 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-002 | Dec 24, 1991 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |